Click here to submit Post PR News
Feedback Form
Pharmaceuticals
Per Page :

Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers

BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH – May 22, 2019 Biocon Ltd. and Mylan N.V. today announced that Health Canada has approved Mylan’s Ogivri™ (trastuzumab), a biosimilar to Herceptin1 (trastuzumab) co-developed with Biocon, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer  →
0 Views : 52

Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification

Bengaluru, India, June 14, 2019 “Biocon has received the Certificate of GMP compliance from EMA for its Biologics Drug Product (DP) as well as Drug Substance (DS) facilities at Biocon Park, Bengaluru. These facilities, used for the manufacture of Biocon’s  →
0 Views : 50

Cipla and Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

Mumbai, February 18, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and Wellthy Therapeutics Private Limited (“Wellthy Therapeutics”) today announced that they have entered into a partnership to offer a combination of pharmacotherapy and  →
0 Views : 170

Cipla receives final approval for generic version of Eli Lilly & Co.’s Adcirca® (Tadalafil Tablets 20mg)

Mumbai, India, February 7, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United  →
0 Views : 159

Cipla receives final approval for generic version of Pfizer’s Depo-Provera® (Medroxyprogesterone Injectable, 150mg/mL )

Mumbai, India, January 28, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United  →
0 Views : 185

Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd., launched generic Methylergonovine tablets in partnership with Hikma

Hyderabad India – May 30th 2018 Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd., has launched the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine in partnership with WestWard Pharmaceuticals Corp. (West-Ward),  →
0 Views : 247

Cipla Receives Final Approval for Generic Depo-Testosterone® (Testosterone Cypionate for Injection 100mg/ml and 200mg/ml)

Mumbai, India, June 21, 2018 Cipla Limited (“Cipla”), today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Testosterone Cypionate Injection 100mg/ml and 200mg/ml from the United States Food and Drug Administration (US FDA).  →
0 Views : 251

Sun Pharma receives EIR for Halol facility

Mumbai, India, June 12, 2018 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol  →
0 Views : 310

Pharmaceutical firms ramp up investment in security products to secure critical data

Pharmaceutical firms require efficient technologies such as Internet of Things (IoT), cloud computing, artificial intelligence and big data to manage info that is important to the development and production of successful drugs. As a result, pharmaceutical corporations are increasing their investment on varied security products to stop breaches, protect patient data and secure sensitive information. According to a survey, 79% of pharmaceutical firms are presently investments in identity  →
0 Views : 291

French pharmaceutical market to stagnate as government holds generics to cut healthcare spending

The pharmaceuticals drugs market in France is prepared to decline from $35.5 billion in 2017 to $34.16 billion in 2021, representing a negative compound annual rate of growth of 1%, according during the forecast period. Latest reports states that in spite of France’s strong public health insurance system and rising senior population, increasing pressure on  →
0 Views : 288



Create Free Account

........................................................................
You can create a free account with us to gain access to just released news and press releases about leading companies from across the world. Your free account can provide you with the latest industry and corporate information to help you take quick business decisions. With your free account, you can be amongst the first ones to know of the latest happenings. So Signup now !!.